Early Adoption of Revised USP <87>, <88>, and <1031>: A Strategic Advantage Before December 2026 As revised USP chapters approach their December 1, 2026 Read More
Transitioning Pharmaceutical Packaging Biocompatibility Programs Without Disruption As pharmaceutical packaging teams prepare for revised USP expectations, Read More
Why USP Class VI Is No Longer Enough for Pharmaceutical Packaging USP Class VI has occupied a central place in Read More
USP <88> Reframed: When In Vivo Testing Is (and Is Not) Appropriate for Pharmaceutical Packaging USP <88> has historically carried outsized weight in pharmaceutical Read More
USP <1031>: The Decision Framework Pharmaceutical Packaging Teams Have Been Missing For many years, pharmaceutical packaging teams faced a familiar Read More
USP <87> Is Changing — What the Expanded In Vitro Framework Means for Pharmaceutical Packaging USP <87> has long been associated with cytotoxicity testing, Read More
Why Pharmaceutical Packaging Biocompatibility Is Moving Beyond Checklists For decades, biocompatibility testing for pharmaceutical packaging followed a Read More
USP <87> Biological Reactivity (In Vitro): A Smart Cytotoxicity Screen for Plastics & Elastomers; From Early Characterization to Release Biocompatibility isn’t a box to check; it’s a continuous Read More
A Basic Overview of ASTM D4169 Distribution Testing ASTM D4169, established by the American Society for Testing Read More
Food and Drug Administration Testing Requirements for Pre-filled Syringes The Food and Drug Administration (FDA) plays a crucial Read More
